



AURORA CAPITAL LLC AND LIFETECH CAPITAL ANNOUNCE STRATEGIC COLLABORATION

New York, NY and Ft. Lauderdale, FL – December 23, 2009 – Aurora Capital LLC, a New York City based investment bank and brokerage firm with principle investment banking activities in the life science sector including biotechnology, today announced that South Florida-and-San Francisco-based LifeTech Capital will become an independent division of the firm’s investment banking group.

The new division will be led by Robert D. Keyser, CEO of LifeTech Capital and Senior Managing Director of Investment Banking, and Stephen M. Dunn, President of LifeTech Capital and Senior Managing Director of Research.

“This is a transformative event for Aurora Capital,” Mr. Margolis, President of Aurora Capital said. “We instantly become a presence in the life-science company PIPE and related financing arenas, which will supplement our existing merchant banking like activities. The businesses are very complimentary, and we expect the relationship to be more than additive.”

The LifeTech Capital division will continue its focus on providing PIPE, overnight and registered direct finance opportunities to the firm’s corporate finance clients, and will provide published life-science research for public distribution. In addition, LifeTech Capital and other divisions of Aurora Capital will collaborate on a number of commercial opportunities.

Among other activities, Mr. Margolis added that Aurora Capital’s public brokerage division will be able to participate in LifeTech Capital’s financings. LifeTech Capital anticipates it will also participate in Aurora’s earlier-stage transactions.

Mr. Keyser stated “I am extremely excited about the combination of LifeTech Capital and Aurora Capital. I believe that the two groups produce a one-stop shop for companies looking to partner with an investment bank and brokerage firm with the expertise and capabilities needed to serve the healthcare and technology sectors.”

Mr. Keyser has over 25 years of experience in all aspects of the securities industry, having founded several private companies, including Dawson James Securities, where he was most recently CEO and remains a major shareholder of its parent company. He has also held various management positions with several securities firms, including Head of Investment Banking, Regional Sales Manager and Branch Manager, with leadership positions in retail and institutional sales, operations, underwriting and syndication, compliance and all general brokerage services. Under Mr. Keyser's leadership Dawson James Securities was among the top 25 agents in the country for the last two years, and was named as one of the top 5 agents in the country for the first quarter of 2006, as reported by Sagient Research Systems.

Mr. Dunn was previously the Managing Director of Life Sciences Research at Jesup & Lamont, as well as Director of Research for Dawson James Securities and Director of Life Sciences at Cabot Adams venture capital group. He has also held management positions in Business Development, Finance and Operations, and has worked in over 25 countries in North America, Europe, and East Asia with biomedical companies, including Beckman Coulter, Coulter, Cordis (Johnson & Johnson), Telectronics (St. Jude Medical). For more than 25 years within the global biomedical industry, Mr. Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, mergers and acquisitions and joint ventures. He is a 5-star biotechnology analyst on StarMine, and has appeared in both the financial and scientific media, such as The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, and BioWorld. He is also a frequent speaker and panel member for many financial, medical and venture capital events.

"The LifeTech Capital team is excited to be joining forces with Aurora Capital," Mr. Dunn said today. "The synergy results in a firm with an unparalleled focus on cutting-edge companies, their technologies, and the potential for capital growth."

Other members of LifeTech Capital joining the team include William D. Dawson, Senior VP Research, and Sachin R. Kelkar, Senior VP Investment Banking. More information on LifeTech Capital will be available soon at www.LifeTechCapital.com

Founded in 1994 by Jeff Margolis, Aurora Capital LLC (www.AuroraCapital.com) is a boutique investment bank and brokerage firm with an experienced team of investment banking professionals specializing in the life sciences sector. For the past 15 years the Aurora teams have dedicated their efforts to providing quality and focused investment banking and strategic consulting and advisory services, and full service investment and brokerage services. In June of 2009, the firm announced the establishment of an India and China Groups, subdivisions responsible for servicing corporate finance clients seeking to do business with Indian and Chinese pharmaceutical and life science entities, as well as other commercial, academic, research, and governmental organizations in the sector.

For more information, contact:

Aurora Capital LLC
Jeff Margolis, President
917-834-7206
jeff@auroracapital.com

LifeTech Capital
Bob Keyser, CEO
561-350-9586
bob@lifetechcapital.com

or

Stephen Dunn, President
954-240-9968
sdunn@lifetechcapital.com